Apixaban

Details

Files

Generic Name:

Apixaban

Project Status:

Complete

Therapeutic Area:

Thromboembolic events prevention, (atrial fibrillation)

Manufacturer:

Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance

Call for patient/clinician input open:

September 7, 2012

Brand Name:

Eliquis

Project Line:

Reimbursement Review

Project Number:

SR0288-000

Call for patient/clinician input closed:

October 15, 2012

NOC Status at Filing:

Pre NOC

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Thromboembolic events prevention, (atrial fibrillation)

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

March 20, 2013

Last Updated : September 25, 2012